Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 10/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.42 |
| ▸ | USP2 | O75604 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9282034 | 1.00 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL9288354 | 0.92 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL9288345 | 0.92 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL9105747 | 0.89 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL9105754 | 0.89 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL9109338 | 0.89 | ADORA3 (0.46) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL9287133 | 0.89 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL9287140 | 0.87 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL16433237 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 | |
| SCHEMBL16433238 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C19CLK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603570-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-03-14 | — | — | US | disclosed |
| US-20200239963-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3027774-B1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10407732-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-09-10 | — | — | US | disclosed |
| US-20160298195-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER | 2016-10-13 | — | — | US | disclosed |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2016-09-01 | — | — | US | disclosed |
| EP-3027774-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | Memorial Sloan Kettering Cancer Center (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9145438-B2 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2646454-B1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2015-07-08 | — | — | EP | disclosed |
| WO-2015017863-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-02-05 | — | — | WO | disclosed |
| US-8722877-B2 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130310334-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2646454-A2 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075500-A2 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | TPMT, HNMT, EHMT1 | CYP1A2 3053/4885CYP3A4 2664/4885CYP2C19 3642/4885 |
| US-20130310334-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | TPMT, HNMT, EHMT1 | CYP1A2 3053/4885CYP3A4 2664/4885CYP2C19 3642/4885 |
| US-11603570-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MLLT1, MCL1, BCR | CYP1A2 3681/4885CYP3A4 3811/4885CYP2C19 4643/4885 |
| US-10407732-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MLLT1, MCL1, BCR | CYP1A2 4353/4885CYP3A4 4158/4885CYP2C19 4794/4885 |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | TPMT, HNMT, EHMT1 | CYP1A2 3053/4885CYP3A4 2664/4885CYP2C19 3642/4885 |
| US-20160298195-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MLLT1, MCL1, BCR | CYP1A2 4353/4885CYP3A4 4158/4885CYP2C19 4794/4885 |
| US-20200239963-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MLLT1, MCL1, BCR | CYP1A2 3681/4885CYP3A4 3811/4885CYP2C19 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.